Antibiotic resistance is a significant global public health threat, with the World Health Organization prioritizing it for research and initiatives. Annually, around 700,000 deaths are attributed to antibiotic-resistant infections, a number that …
Antimicrobial resistance (AMR) poses a significant threat to cancer patients due to their compromised immune systems and frequent exposure to antibiotics during treatment. A systematic review reveals a high prevalence of AMR among bacterial pathogens …
The article discusses the critical role of Antimicrobial Stewardship (AMS) in primary care, emphasizing its importance in combating antimicrobial resistance (AMR) through optimal antibiotic use. Effective AMS ensures patients receive appropriate …
This article discusses the challenges of diagnosing pleural infections—conditions like empyema and complicated parapneumonic effusions—and highlights the limitations of traditional culture-based methods, which often yield low positivity rates due to …
Clostridioides difficile infection (CDI) is a major public health issue, affecting around 500,000 patients annually in the U.S. and leading to significant healthcare costs estimated between $5.4 to $6.3 billion. CDI is often linked to antibiotic use, …
The article discusses effective strategies for managing early-onset sepsis (EOS) in preterm infants, a serious bacterial infection occurring within the first 72 hours after birth, particularly affecting very low birth weight (VLBW) infants. Key risk …
The article emphasizes the vital role healthcare professionals, including physicians, pharmacists, and nurses, play in educating patients about antibiotic use and combating antimicrobial resistance (AMR). Effective communication and tailored …
Dificid is a narrow-spectrum antibiotic specifically designed to treat Clostridioides difficile infections (CDI), known for its minimal impact on the gut microbiome, which helps reduce recurrence rates compared to traditional treatments like …
The article “Understanding C. Diff: Causes and Risk Factors for Recurrence” discusses Clostridium difficile (C. diff) infections, which arise when the gut’s bacterial balance is disrupted, often due to antibiotic use. C. diff …
Clostridium difficile (C. diff) is a spore-forming bacterium that can cause gastrointestinal issues, ranging from mild diarrhea to severe colitis, particularly when the gut flora is disrupted, often due to antibiotic use. Most infections occur in …
Fecal transplantation, or fecal microbiota transplantation (FMT), is a procedure that involves transferring fecal matter from a healthy donor to a recipient’s gastrointestinal tract to restore gut microbiota balance. This treatment has shown …
Vowst is a biologic drug designed to prevent recurrent Clostridioides difficile (C. diff) infections by utilizing fecal microbiota spores derived from healthy donors. It functions as a fecal microbiota transplant (FMT), restoring beneficial gut …
C. diff, or Clostridioides difficile, is a bacterium that can cause severe gastrointestinal infections, particularly after antibiotic use, which disrupts the gut’s healthy bacteria. Key risk factors for C. diff infections include recent …
